Immensa is the application of “immersion,” which includes taking a person’s physical body and suspending it in amniotic fluid to reduce discomfort and make them more susceptible to outside stimuli. Immersions are typically applied through nasal or oral tubes that provide fluids to the lungs or digestive tract.
This application, designed to be administered to infants and toddlers, has been practiced as an arnals.
The “Immense” process is performed at hospitals and clinics in Switzerland, the United States, and other states worldwide.
Currently, such Immensa treatments are only submitted to medical testing within the framework of clinical trials. At present, there are only four clinical studies that have been completed with patients who were treated with “Immensa.
The ongoing studies involve patients from Switzerland, France, the United States, and Japan.
According to the Ministry of Health in Switzerland, the World Health Organization (WHO) has approved this therapy for “injection” or “swallow” and for children younger than one-year-old.
It is practiced as “drowning” or “swallowing” in Switzerland and France. In the United States, it is administered as a “transparent tube” that passes through the nose and into the lungs to administer medication or fluids. In Japan, I have prescribed a transparent tube through the nose and gastrointestinal tract to deliver various medicines during treatments.
The treatment applies two methods for immersion – drowning and swallowing – for children less than one-year-old. A French doctor and a group of scientists from the United States filed two internationally pending patents.
The immersion method and device for treating autism, neurological, psychiatric, and other disorders are described in U.S. Patent Application No. 15/720,744 filed on July 21, 2017, for Bathsheba Haywood and Jean-Marc Bonnet-Brilhault, “Immersion Method And Device For Treating Autism.”